SignalEU/UK
Bayer gains approval of Factor XIa inhibitor asundexian to reduce stroke risk
Bayer's asundexian approval targets stroke risk reduction, a significant regulatory catalyst.
Context
What happened: The US FDA approved Bayer's (BAYRY) Sunharbo (asundexian) for secondary stroke prevention in patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Why it matters: The approval covers a first-in-class Factor XIa inhibitor taken in combination with antiplatelet therapy, giving Bayer a new treatment option in this prevention setting.
What changed
The US FDA approved Bayer's (BAYRY) Sunharbo (asundexian) for secondary stroke prevention in patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Why it matters
The approval covers a first-in-class Factor XIa inhibitor taken in combination with antiplatelet therapy, giving Bayer a new treatment option in this prevention setting.